kalvista.com
KalVista Pharmaceuticals Ltd -
http://kalvista.com/about/overview.php
UK: 44 (0)1980 753002. USA: 1 (857) 241 3897. Creating a new generation of small molecule protease inhibitors. KalVista is a pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors as new treatments for diseases with significant unmet needs. The Company features an R&D team with an established track record in the pharmaceutical development of small molecule protease inhibitors, world-leading expertise in the role of plasma kallikrein in dis...
kalvista.com
KalVista Pharmaceuticals Ltd - Senior Management
http://kalvista.com/about/investors.php
UK: 44 (0)1980 753002. USA: 1 (857) 241 3897. Creating a new generation of small molecule protease inhibitors. RA Capital’s scientifically trained research team is intensely data driven in its continual effort to identify early breakthroughs and originate conviction in new ideas. The team’s understanding of industry best practices is derived from an extensive collection of case studies documenting the impact of clinical trial design, partnership structures, public market dynamics, and many other fact...
kalvista.com
KalVista Pharmaceuticals Ltd - News Article
http://www.kalvista.com/press/articles/KalVista-Pharmaceuticals-Raises-33-Million-Dollars-to-Advance-Development-of-Novel-Plasma-Kallikrein-Inhibitors-in-DME-and-HAE.php
UK: 44 (0)1980 753002. USA: 1 (857) 241 3897. Creating a new generation of small molecule protease inhibitors. KalVista Pharmaceuticals Raises $33 Million to Advance Development of Novel Plasma Kallikrein Inhibitors in Diabetic Macular Edema and Hereditary Angioedema. Boston, MA, USA and Salisbury, UK. 22 July 2015. KalVista is also rapidly advancing orally delivered inhibitors through pre-clinical testing. These drugs will not only expand the therapeutic options for DME patients but also enable KalV...
nktrx.com
NKT Therapeutics Inc - Investors
http://www.nktrx.com/investors.html
Precisely targeting the interface between. Innate and adaptive immunity. NKTT120 Granted Fast Track Designation. NKTT Presents Data at the 2014 FSCDR Meeting. NKTT Presents Data at the 2014 AACR Annual Meeting. NKTT Presents Data at the 2013 ASH Annual Meeting. NKTT Presents Data at 2013 National SCD Meeting. NKTT Announces Preclinical Data at ASH 2012. BIOWA and NKTT announce licensing of BIOWAs Potelligent Technology. Selexis and NKT Therapeutics enter into Agreement.
svlsm.com
SV Life Sciences Team
http://www.svlsm.com/pages/team.html
SVLS Managers - Team. SV Life Sciences Managers. Has been Managing investments for International Biotechnology Trust plc since January 2005, though SV Life Sciences was involved in advising the trust for the period since November 2000. Carl Harald is the lead manager of the fund and joined the firm in September 2013. Further information is available at www.svlsa.com. And www.theDDFund.com.
avitide.com
Avitide | On-Demand Affinity Purification Solutions
http://avitide.com/founding-team
Without compromise to yield, purity, or quality. ON-DEMAND MOLECULE-SPECIFIC AFFINITY RESINS. Solutions in 3 months. Avitide is dedicated to advancing our partners clinical pipelines and commercial manufacturing processes with a rapid, exclusive, and enabling affinity purification platform technology. Avitide partners benefit from:. Every affinity resin discovery campaign is exclusive to our Partners. Partners receive an exclusive license to key bioprocess technology and intellectual property for the...